JPH0530777Y2 - - Google Patents

Info

Publication number

JPH0530777Y2

JPH0530777Y2 JP7325688U JP7325688U JPH0530777Y2 JP H0530777 Y2 JPH0530777 Y2 JP H0530777Y2 JP 7325688 U JP7325688 U JP 7325688U JP 7325688 U JP7325688 U JP 7325688U JP H0530777 Y2 JPH0530777 Y2 JP H0530777Y2

Authority

JP

Japan

Prior art keywords

drug

skin

drugs

inlet

container

Prior art date

1988-05-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Lifetime

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims description 69
• 229940079593 drug Drugs 0.000 claims description 69
• 230000010355 oscillation Effects 0.000 claims description 10
• 230000002262 irrigation Effects 0.000 claims 1
• 238000003973 irrigation Methods 0.000 claims 1
• 210000003491 skin Anatomy 0.000 description 15
• 238000000034 method Methods 0.000 description 6
• 239000008280 blood Substances 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 238000010521 absorption reaction Methods 0.000 description 4
• 238000001647 drug administration Methods 0.000 description 4
• 230000000694 effects Effects 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• 230000010412 perfusion Effects 0.000 description 4
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 239000002547 new drug Substances 0.000 description 3
• 102000011782 Keratins Human genes 0.000 description 2
• 108010076876 Keratins Proteins 0.000 description 2
• 239000000919 ceramic Substances 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000008105 immune reaction Effects 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 210000000434 stratum corneum Anatomy 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 206010019670 Hepatic function abnormal Diseases 0.000 description 1
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 239000000006 Nitroglycerin Substances 0.000 description 1
• 230000037374 absorbed through the skin Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940127088 antihypertensive drug Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• JRPBQTZRNDNNOP-UHFFFAOYSA-N barium titanate Chemical compound [Ba+2].[Ba+2].[O-][Ti]([O-])([O-])[O-] JRPBQTZRNDNNOP-UHFFFAOYSA-N 0.000 description 1
• 229910002113 barium titanate Inorganic materials 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
• 229950003631 carpronium chloride Drugs 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• NKZSPGSOXYXWQA-UHFFFAOYSA-N dioxido(oxo)titanium;lead(2+) Chemical compound [Pb+2].[O-][Ti]([O-])=O NKZSPGSOXYXWQA-UHFFFAOYSA-N 0.000 description 1
• 201000010099 disease Diseases 0.000 description 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• -1 etc. Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 229960003711 glyceryl trinitrate Drugs 0.000 description 1
• 230000020169 heat generation Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
• 229960002646 scopolamine Drugs 0.000 description 1
• 230000037384 skin absorption Effects 0.000 description 1
• 231100000274 skin absorption Toxicity 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 229910052845 zircon Inorganic materials 0.000 description 1
• GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1